Great news for eligible HAE patients in PEI. Lanadelumab (TAKHZYRO), a subcutaneous injection to routinely prevent attacks in patients with HAE Type I or II (12 years old and up) was added to PEI’s drug formulary. There are a couple of sites that you can visit to learn more:
- PEI Pharmacare Bulletin (see page 3)
- Takeda’s reimbursement site
We want to thank the amazing people at Takeda who worked very hard to ensure Canadians across the country have access to this prophylactic treatment. Thank you to the PEI government officials who recognized the importance of adding Takhzyro to the PEI formulary.
We are so pleased that this treatment is now available in each province.